FindTrial
Sign In

A study to compare the safety and moisturizing effects of a skincare product in healthy women.

To evaluate and compare the in-vivo safety and efficacy of Skin Care Formulation versus Untreated Control in terms of skin moisturisation, skin softness, skin smoothness and skin barrier function on healthy female subjects - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102012
Enrollment
33
Registered
2026-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Moha Face Moisturizer (AL0555): 20 l of the test product will be applied to randomized 3 3 cm sites on the forearm. The product will be gently spread using a finger cot and left uncov

Sponsors

Vedistry Pvt Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Indian or Asian female subjects 2.Healthy subjects 3.Skin is healthy on the studied anatomic unit 4.Subject having dry skin type.

Exclusion criteria

Exclusion criteria: 1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2. Having refused to give her/his assent by not signing the consent form 3. Taking part in another study liable to interfere with this study 4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5. Having a progressive asthma (either under treatment or last fit in the last 2 years) 6. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8. Being epileptic. 9. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 10. Having cutaneous hypersensitivity. 11. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 12. Having undergone a surgery requiring a general anesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Skin moisturisation, skin softness, skin smoothness and skin barrier functionTimepoint: Baseline, 30 min. after product application , 48 Hours after product application , 72 Hours after product application—

Secondary

MeasureTime frame
NilTimepoint: NA—

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

niharika@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026